^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy
Published date:
11/27/2020
Excerpt:
Exelixis, Inc....today announced that Takeda Pharmaceutical Company Limited (Takeda)...received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX as a treatment for patients with unresectable hepatocellular carcinoma (HCC) that has progressed after prior systemic therapy.
Source:
Title:
Health Canada approves CABOMETYX (cabozantinib) Giving Physicians and Adult Patients a New Second-Line Option in the Fight Against Advanced Hepatocellular Carcinoma
Published date:
11/12/2019
Excerpt:
Ipsen Biopharmaceuticals Canada Inc. today announced the Health Canada approval of CABOMETYX (cabozantinib) for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Source:
Published date:
09/09/2016
Excerpt:
Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.
Source:
Excerpt:
CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
Source:
Title:
Ipsen’s cabozantinib receives NICE approval for advanced hepatocellular carcinoma
Published date:
11/10/2022
Excerpt:
Ipsen’s cabozantinib has been recommended by the National Institute for Health and Care Excellence (NICE) as an option for patients with previously treated advanced hepatocellular carcinoma (HCC).
Source:
Title:
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline
Published date:
11/16/2020
Excerpt:
Recommendations...First-Line Therapy...Where there are contraindications to atezolizumab and/or bevacizumab, tyrosine kinase inhibitors (TKIs) sorafenib or lenvatinib may be offered as first-line treatment of patients with advanced HCC…Second-Line Therapy...second-line therapy with a TKI (ie, sorafenib, lenvatinib, cabozantinib, or regorafenib) may be recommended...second-line therapy with another TKI (cabozantinib or regorafenib), ramucirumab (AFP ≥ 400 ng/mL)...
DOI:
0.1200/JCO.20.02672 Journal of Clinical Oncology
Source:
Title:
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Excerpt:
Management of advanced disease...Cabozantinib can be considered for patients who had progressive disease on one or two systemic therapies with well-preserved liver function and ECOG PS 0–1, pending EMA approval [I, A]
DOI:
10.1093/annonc/mdy308
Source:
Excerpt:
The panel now recommends several subsequent-line therapy options for patients with disease progression following systemic therapy. Category 1 options include regorafenib, cabozantinib, and ramucirumab. Regorafenib and cabozantinib are recommended only for patients with C-P A liver function, while ramucirumab is recommended only for patients with a baseline AFP level of 400 ng/mL or greater.
Source:
Title:
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Excerpt:
Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo.
DOI:
10.1056/NEJMoa1717002
Trial ID:
